MedicineNews.net - Medical Updates

Tivozanib in combination with Nivolumab in renal cell carcinoma: interim results from phase 2 portion of the TiNivo trial

Updated interim results from the phase 2 portion of the TiNivo study, a phase 1b/2 multicenter trial of oral Tivozanib ( Fotivda ) in combination with intravenous Nivolumab ( Opdivo ), an immune check ... read article

Mvasi, a biosimilar to the cancer drug Avastin, approved from FDA for certain colorectal, lung, brain, kidney and cervical cancers

The FDA ( Food and Drug Administration ) has approved Mvasi ( Bevacizumab-awwb ) as a biosimilar to Avastin ( Bevacizumab ) for the treatment of multiple types of cancer. Mvasi is the first biosimil ... read article

Candesartan or other sartans could have a role in Alzheimer's disease treatment

According to researchers at Georgetown University Medical Center ( GUMC ) and at National Institutes of Health ( NIH ), in laboratory neuronal cultures, a drug used to treat high blood pressure reduc ... read article

Treatment of hypertension induced albuminuria

Albuminuria is a renal disease that is found to be independently associated with cardiovascular and renal problems without any links to diabetes. In latest ESC/ESH guidelines, microalbuminuria has ... read article

Symptoms of insomnia in psoriasis are directly mediated by pruritus and pain

Psoriasis is an immune-mediated chronic inflammatory disorder which manifests as dermatologic lesions, and psoriatic arthritis in about 30% of cases. Psoriasis is associated with multiple comorbid ... read article

High-normal blood pressure in young adults linked to risk of heart failure in later life

Mild elevations in blood pressure considered to be in the upper range of normal during young adulthood can lead to subclinical heart damage by middle age, a condition that sets the stage for full-blow ... read article

NSCLC: significant improvement in the primary endpoint of overall survival in the Ramucirumab arm

Eli Lilly has announced that the randomized, double-blind, REVEL trial, a global phase III study of Ramucirumab in combination with chemotherapy in patients with second-line non-small cell lung carcin ... read article

Lenvatinib, a thyroid cancer drug meets primary endpoint in phase 3 study

Eisai has announced that the phase 3 SELECT trial ( Study 303 ) of investigational agent Lenvatinib met its primary endpoint. Compared to placebo, Lenvatinib showed a highly statistically significant ... read article

Opsumit to treat pulmonary arterial hypertension, FDA approved

The Food and Drug Administration ( FDA ) has approved Opsumit ( Macitentan ), a new drug to treat adults with pulmonary arterial hypertension ( PAH ), a chronic, progressive and debilitating disease t ... read article

Safety information about Myrbetriq, a drug for treatment of overactive bladder

Myrbetriq ( Mirabegron ) is a beta- 3 adrenergic agonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Important safe ... read article

Cardiometabolic adverse reactions suspected of being associated with second-generation antipsychotics in children and adolescents

Excess weight and obesity in the general population are increasing problems throughout the Western world, and this rise has also been observed in children and adolescents.Weight gain and obesity are k ... read article

Canagliflozin as add-on therapy to Metformin and Pioglitazone significantly lowers blood sugar levels in adult patients with type 2 diabetes

Janssen has announced that the investigational agent Canagliflozin substantially lowers blood glucose levels compared to placebo when used as add-on therapy in patients with type 2 diabetes who are in ... read article

Stivarga for treatment of metastatic colorectal cancer approved by FDA

Bayer HealthCare has announced that the Food and Drug Administration ( FDA ) approved Stivarga ( Regorafenib ) tablets for the treatment of patients with metastatic colorectal cancer ( mCRC ) who have ... read article

Reductions in risk of CHD mortality and cardiovascular events with Simvastatin

The Heart Protection Study ( HPS ), a large, multicenter, placebo-controlled, double-blind study with a mean duration of 5 years conducted in 20,536 patients, including 5,963 patients with type 2 diab ... read article

Association found between renal cell cancinoma and long-term use of non-Aspirin anti-inflammatory drugs

Long-term use of non-Aspirin anti-inflammatory drugs ( NSAIDs ) is associated with an increased risk of renal cell cancer ( RCC ).In the United States, kidney cancer is the seventh leading type of can ... read article